Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Alterity Therapeutics.
RELATED STOCKHEAD STORIES
News
Top 10 at 11: Boardroom battles and spinning drills are driving the market this morning
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: The ASX is slightly higher, but not much cooler on Monday
Health & Biotech
ASX Health Stocks: HeraMED jumps 30pc after maternity care platform goes live at clinical trial
Health & Biotech
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Health & Biotech
Orphan drug designation has a direct impact on drug pricing for these pharma players
Health & Biotech
ASX Health Stocks: Patrys’ drug exhibits cancer lethality, US Patent Office says yes to Alterity
Health & Biotech
As dementia takes toll on Aussies, here’s why Alterity and these ASX biotechs are in the box seat
News
CLOSING BELL: Why mortgage holders should say ‘thanks a bunch’ to everyone who got canned in January
News
Closing Bell: This is what it looks like to have a billion dollar target on your back
Investor Guides
Investor Guide: Health & Biotech FY2023
Health & Biotech
ASX Health Stocks: Alterity jumps 20pc after FDA approves its clinical trial in the US
Health & Biotech
This ASX stock is watching you while you sleep… because it could point to Parkinson’s disease
Health & Biotech
ASX Health Stocks: ResApp gets FDA nod, while Japan grants Immutep a patent
Health & Biotech
ASX Health Stocks: Trajan rattles the tin in further $5 million cap raise
Health & Biotech
Check Up: Biotechs are getting crushed, but expert says we shouldn’t dismiss them
Health & Biotech
